MedPath

Effects of Jinshui Huanxian granules for patients with PPF:A Multiceter,randomized,double-blind,placebo-controlled trial

Not Applicable
Not yet recruiting
Conditions
Pulmonary fibrosis
Registration Number
ITMCTR2200006437
Lead Sponsor
The First Affiliated Hospital of Henan University of CM
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1.Patients diagnosed with PPF;2.Aged 18 or older;3.Comply with TCM syndrome differentiation standards;4.Not participate in any other drug trial within one month prior to enrollment;5.FEV1/FVC=70% before bronchodilator use;6.FVC% predicted =45%;7.Dlco% predicted corrected for normal hemoglobin (Hb) normal = 30%–< 80%;8.Sign informed consent forms.

Exclusion Criteria

1.Patients diagnosed with IPF;2.patients with confused,dementia,various mentally ill people and cannot communicate normally;3.Paitients with acute exacerbation of PPF ;4.Major extra-pulmonary physiologic limitation(eg chest wall abnormalities,massive of pleural effusion);5.Tumor before screening (except localized cancer such as basal cell carcinoma)within 5 year;6.Unstable or worsening heart disease within 6 months prior to screening,including but not limited to the following:myocardial infarction;unstable angina;congestive heart failure (requiring treatment in hospital or NYHA III/IV);uncontrolled severe cardiac arrhythmia;7.TBIL>1.2×ULN,AST or ALT>1.5×ULN;8.CLcr<60ml/min;9.Use of any of the following drugs to treat interstitial lung disease(ILD):strong inducers or strong CYP3A4 inhibitors within 4 weeks before randomization;Azathioprine (AZA),cyclosporine,MMF,combination of tacrolimus,oral corticosteroid(OCS)>20mg/ day,and OCS+AZA+NAC;cyclophosphamide within 8 weeks prior to randomization;Rituximab within 6 months prior to randomization;10.Unable to complete PFT,6MWT,or questionnaire;11.Pregnant or lactating women.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.